Peptide LibraryOrforglipron dosage in published studies and labels
These are the doses used for Orforglipron in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Orforglipron has an FDA-approved human dosage. It was approved in April 2026 as FOUNDAYO, a once-daily oral tablet for reducing excess body weight and maintaining the reduction long term in adults with obesity, or overweight with at least one weight-related condition. The label starts at 0.8 mg once daily and escalates after at least 30 days at each step, to 2.5 mg and then 5.5 mg; the dose may then be raised to 9 mg, 14.5 mg or 17.2 mg, and 17.2 mg once daily is the maximum. Orforglipron is a small-molecule, non-peptide GLP-1 receptor agonist taken with or without food, and there is no injectable form.
FDA Approved
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.8–17.2 mg once daily (FOUNDAYO tablets) |
| Route | Oral |
| Frequency | Once daily, with or without food |
| Duration studied | Long term; at least 30 days at each dosage before escalating |
| Titration | 0.8 mg once daily for at least 30 days, then 2.5 mg once daily for at least 30 days, then 5.5 mg once daily. After at least 30 days at the current dosage the dose may be raised to the next level (9 mg, 14.5 mg, then 17.2 mg) based on response and tolerability. Maximum 17.2 mg once daily. If 7 or more consecutive doses are missed, escalation restarts at a lower dosage. |
| Half-life | Approximately 29–49 hours after an oral dose; steady state after about 1 week of daily dosing |
| Evidence level | FDA Approved |
| Last reviewed | 2026-10-05 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — FOUNDAYO, weight reduction and long-term maintenanceFDA-approved label · FDA prescribing information | Adults with obesity, or with overweight and at least one weight-related comorbid condition | 0.8 mg starting dose, escalated to 2.5 mg and then 5.5 mg; may be increased to 9 mg, 14.5 mg or 17.2 mg; maximum 17.2 mg | Oral tablet, swallowed whole | Once daily, with or without food | Long term, alongside a reduced-calorie diet and increased physical activity | Reduction of excess body weight and long-term maintenance of the reduction | FOUNDAYO (orforglipron) tablets — FDA prescribing information, DailyMed |
| ATTAIN-1 — phase 3 obesity trial without diabetes, investigational formulation (NCT05869903)Clinical trial · Phase 3 double-blind randomised placebo-controlled trial | Adults with obesity, or overweight with a weight-related condition, without diabetes (n=3127) | 6 mg, 12 mg or 36 mg | Oral | Once daily | 72 weeks | Percentage change in body weight at week 72 — −7.5%, −8.4% and −11.2% with 6, 12 and 36 mg versus −2.1% with placebo | Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment. N Engl J Med. 2025. |
| ATTAIN-2 — phase 3 obesity trial in type 2 diabetes, investigational formulation (NCT05872620)Clinical trial · Phase 3 double-blind randomised placebo-controlled trial | Adults with BMI ≥27 and type 2 diabetes with HbA1c 7–10% (n=1613) | 6 mg, 12 mg or 36 mg | Oral | Once daily | 72 weeks | Percentage change in body weight at week 72 — −5.1%, −7.0% and −9.6% with 6, 12 and 36 mg versus −2.5% with placebo | Horn DB et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025. |
| ACHIEVE-3 — phase 3 against oral semaglutide in type 2 diabetes (NCT06045221)Clinical trial · Phase 3 open-label randomised active-controlled non-inferiority trial | Adults with type 2 diabetes inadequately controlled with metformin, HbA1c 7.0–10.5% and BMI ≥25 (n=1698) | 12 mg or 36 mg | Oral | Once daily | 52 weeks | Change in HbA1c at week 52 versus oral semaglutide 7 mg and 14 mg — both orforglipron doses were non-inferior and superior, with more gastrointestinal events and more discontinuations due to adverse events | Rosenstock J et al. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026. |
Where sources disagree
- Orforglipron is not a peptide. It is a small-molecule, non-peptide GLP-1 receptor agonist, supplied as orforglipron calcium, and it is listed alongside peptides because it acts on the same receptor as semaglutide and tirzepatide. It is also not oral semaglutide (Rybelsus): that is a tablet form of a peptide, with a different molecule, label and dose scale.
- There is no injectable orforglipron. FOUNDAYO is a film-coated tablet, and the label states it is only for oral use and describes orforglipron calcium as insoluble in water. No registered trial gives orforglipron by subcutaneous injection; the only non-oral dosing in the registered programme is an intravenous radiolabelled tracer in a phase 1 pharmacokinetic study (NCT06085482). Vials sold as orforglipron for reconstitution and injection are not the approved product, and no published study supports their dosing.
- Trial doses and tablet strengths are not interchangeable milligram for milligram. The phase 3 trials used an investigational formulation and report doses of 6, 12 and 36 mg once daily; the FOUNDAYO label presents the same trial arms as equivalent dosages of 5.5, 9 and 17.2 mg. A trial figure such as 36 mg describes that formulation and is above the 17.2 mg label maximum, so it should not be read as a FOUNDAYO dose.
- The FOUNDAYO label directs one tablet once daily with or without food, swallowed whole and not broken, crushed or chewed, and sets no fasting period or water limit. The oral semaglutide label requires an empty stomach with up to 4 ounces of water and a 30-minute wait before eating, so administration rules written for one should not be applied to the other.
- The label's only indication is weight reduction and long-term weight maintenance in adults. Type 2 diabetes trials such as ACHIEVE-3 report glycaemic results, but as of the July 2026 label revision orforglipron is not approved for glycaemic control; people with type 2 diabetes appear on the label only within the weight-management indication (ATTAIN-2).
- The 0.8 mg and 2.5 mg dosages are escalation steps, and the label's efficacy data come from arms equivalent to 5.5, 9 and 17.2 mg, so 14.5 mg is a labelled step without its own randomised arm in those trials. The label also lowers the maximum to 9 mg once daily alongside a strong CYP3A4 inhibitor, advises avoiding strong CYP3A4 inducers, and does not recommend use in severe hepatic impairment, so a single maximum dose depends on concomitant medicines.